mouse monoclonal IgG2a; GILZ Antibody (G-5) is an IgG2a κ mouse monoclonal GILZ antibody (also designated TSC22D3 antibody, T22D3 antibody, TSC22 Domain Family Member 3 antibody, TSC-22R antibody, GILZ antibody, Glucocorticoid-Induced Leucine Zipper Protein antibody, Delta Sleep-Inducing Peptide Immunoreactor antibody, TSC22 Domain Family Protein 3 antibody, DSIP-Immunoreactive Peptide antibody, TSC-22-Like Protein antibody, DSIPI antibody, HDIP antibody, DIP antibody, Delta Sleep Inducing Peptide Immunoreactor antibody, or DSIP-Immunoreactive Leucine Zipper Protein antibody) that detects the GILZ protein of human origin by WB, IP, IF, IHC(P) and ELISA. GILZ Antibody (G-5) is available as both the non-conjugated anti-GILZ antibody form, as well as multiple conjugated forms of anti-GILZ antibody, including agarose, HRP, PE, FITC and multiple Alexa Fluor® conjugates. Glucocorticoid-induced leucine zipper (GILZ) is a leucine zipper protein expressed in normal lymphocytes from thymus, spleen and lymph nodes. It is absent in nonlymphoid tissues including brain, liver and kidney. GILZ mediates the immunosuppressive effects of glucocorticoid hormones; its expression is induced in T cells by dexamethasone. GILZ protects T cells from an anti-CD3 antibody-induced apoptosis by inhibiting Fas and Fas ligand expression. It interferes with Egr-2, Egr-3, NFAT/AP-1-inducible transcription factors and AP-1. The interaction of GILZ with c-Fos and c-Jun inhibits the binding of active AP-1 to its DNA consensus site in vitro. GILZ also binds NFkB subunits and inhibits the NFkB nuclear translocation. It inhibits T cell receptor-induced interleukin-2/interleukin-2 receptor expression. The binding of GILZ to Raf-1 prevents Raf-MEK-ERK activation in the MAPK pathway. GILZ is expressed by normal macrophages in nonlymphoid tissues and by tumor-infiltrating macrophages in Burkitt lymphomas. The gene encoding human GILZ maps to chromosome Xq22.3.